By Sriparna Roy and Pratik Jain (Reuters) – A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD). The meeting by the agency’s independent experts is the farthest…